Literature DB >> 26605922

Management of severe osteoporosis.

Paul D Miller1.   

Abstract

INTRODUCTION: Severe osteoporosis represents a disease of high mortality and morbidity. Recognition of what constitutes and causes severe osteoporosis and aggressive intervention with pharmacological agents with evidence to reduce fracture risk are outlined in this review. AREAS COVERED: This review is a blend of evidence obtained from literature searches from PubMed and The National Library of Medicine (USA), clinical experience and the author's opinions. The review covers the recognition of what constitutes severe osteoporosis, and provides up-to-date references on this sub-set of high risk patients. EXPERT OPINION: Severe osteoporosis can be classified by using measurements of bone densitometry, identification of prevalent fractures, and, knowledge of what additional risk factors contribute to high fracture risk. Once recognized, the potential consequences of severe osteoporosis can be mitigated by appropriate selection of pharmacological therapies and modalities to reduce the risk for falling.

Entities:  

Keywords:  Management of severe osteoporosis; pharmacological therapy of severe osteoporosis; severe osteoporosis; treatment of high risk osteoporotic patients

Mesh:

Year:  2015        PMID: 26605922     DOI: 10.1517/14656566.2016.1124856

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  43 in total

1.  Neohesperidin promotes the osteogenic differentiation of bone mesenchymal stem cells by activating the Wnt/β-catenin signaling pathway.

Authors:  Yue-Wen Chang; Wen-Jun Zhu; Wei Gu; Jun Sun; Zhi-Qiang Li; Xiao-En Wei
Journal:  J Orthop Surg Res       Date:  2021-05-21       Impact factor: 2.359

2.  The mechanism of miR-889 regulates osteogenesis in human bone marrow mesenchymal stem cells.

Authors:  Gang Xu; Zheng Ding; Hui-Feng Shi
Journal:  J Orthop Surg Res       Date:  2019-11-14       Impact factor: 2.359

3.  A novel ceRNA regulatory network involving the long noncoding NEAT1, miRNA-466f-3p and its mRNA target in osteoblast autophagy and osteoporosis.

Authors:  Xiaobing Zhao; Dacheng Zhao; Bin Geng; Wang Yaobin; Yayi Xia
Journal:  J Mol Med (Berl)       Date:  2022-09-28       Impact factor: 5.606

4.  The effect of SOX4 gene 3'UTR polymorphisms on osteoporosis.

Authors:  Guo Li; Zuchao Gu; Yue He; Chongwen Wang; JiQiang Duan
Journal:  J Orthop Surg Res       Date:  2021-05-18       Impact factor: 2.359

5.  Associations of Health-Related Quality of Life, Fear of Falling and Objective Measures of Physical Function with Bone Health in Postmenopausal Women with Low Bone Mass.

Authors:  Anoohya Gandham; Lachlan B McMillan; Carrie-Anne Ng; Ludovic Humbert; Maxine P Bonham; Ayse Zengin; Peter R Ebeling; David Scott
Journal:  J Clin Med       Date:  2019-09-02       Impact factor: 4.241

6.  Exploring the Mechanism of Icariin in Osteoporosis Based on a Network Pharmacology Strategy.

Authors:  Zhiyong Long; Jiamin Wu; Wang Xiang; Zhican Zeng; Ganpeng Yu; Jun Li
Journal:  Med Sci Monit       Date:  2020-11-24

7.  Vertebral bone marrow T2* mapping using chemical shift encoding-based water-fat separation in the quantitative analysis of lumbar osteoporosis and osteoporotic fractures.

Authors:  Yannik Leonhardt; Florian T Gassert; Georg Feuerriegel; Felix G Gassert; Sophia Kronthaler; Christof Boehm; Alexander Kufner; Stefan Ruschke; Thomas Baum; Benedikt J Schwaiger; Marcus R Makowski; Dimitrios C Karampinos; Alexandra S Gersing
Journal:  Quant Imaging Med Surg       Date:  2021-08

8.  Implications of gender-based variabilities in bone mineral density and hemoglobin levels.

Authors:  Yumei Zhou; Shengjun Liu; Ximei Wang; Yuhan Fu; Fan Su; Lei Cao; Xiaojuan Zha; Yufeng Wen
Journal:  BMC Musculoskelet Disord       Date:  2021-07-30       Impact factor: 2.362

9.  Opportunistic QCT Bone Mineral Density Measurements Predicting Osteoporotic Fractures: A Use Case in a Prospective Clinical Cohort.

Authors:  Yannik Leonhardt; Pauline May; Olga Gordijenko; Veronika A Koeppen-Ursic; Henrike Brandhorst; Claus Zimmer; Marcus R Makowski; Thomas Baum; Jan S Kirschke; Alexandra S Gersing; Vanadin Seifert-Klauss; Benedikt J Schwaiger
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-09       Impact factor: 5.555

10.  Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.

Authors:  Qingshan Liu; Dongmei Chen; Zongjian Ye; Zhaoming Jin; Tao Ma; Xuemei Huang
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.